Key result
Micra AV atrial undersensing triggers polymorphic VT, resolving after sensing parameter reprogramming.
Why the study?
Leadless pacing offers a favorable safety and efficacy profile in selected patients but its complications, including arrhythmias after AV synchronous leadless pacemaker implantation, require further characterization.
Case Report (n=1)
Raises awareness of polymorphic VT risk after Micra AV implantation; single case leaves open incidence and optimal sensing strategies.
Leadless pacing is an alternative to transvenous single-chamber ventricular pacing (VVI/R) with a favorable safety and efficacy profile in selected patients.1 Until recently, the Micra (Model MC1VR01; Medtronic Inc, Minneapolis, MN) was the only leadless pacing system approved for clinical use in the United States. The leadless pacemaker is an attractive option for patients with permanent atrial fibrillation who require infrequent ventricular back-up pacing and in those in whom atrioventricular (AV) synchrony is not pursued, especially when vascular access is limited (ie, hemodialysis patients) or the risk of intravascular infection is deemed high.
No takes yet. Share an insight, caveat, or question.
Halawa et al. (2020) conducted a case report in Complete heart block (n=1). Micra AV leadless pacemaker was evaluated. Implantation of a Micra AV leadless pacemaker caused bradycardia-dependent polymorphic ventricular tachycardia due to atrial undersensing, which resolved after adjusting sensing parameters.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: